Skip to content
ClinCalc Pro
Menu
Paraffin-based bath/shower emollient

Emollient bath and shower products, paraffin-containing

Brand names: Oilatum, Balneum, Hydromol Bath

These are paraffin-containing emollient bath additives and shower preparations used to soften and moisturise the skin in dry skin conditions such as eczema and ichthyosis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

The paraffin oils coat the skin during bathing to form an occlusive layer that reduces transepidermal water loss and restores the skin barrier.

Prescribing in practice

  • Paraffin-based products soak into fabrics and create a serious fire hazard, so patients and carers must be warned that clothing, bedding and dressings can ignite more easily near naked flames or cigarettes.
  • Treated baths and showers become very slippery, posing a falls risk that warrants non-slip precautions.
  • Direct evidence that bath additives add benefit over leave-on emollients is limited, so they should be used as an adjunct rather than a substitute for regular emollient application.

Monitoring

No laboratory monitoring is needed; review skin condition, tolerability and adherence to fire-safety advice at follow-up.

Counselling the patient

  • Keep away from naked flames and do not smoke; fabrics in contact with these products burn very easily even after washing.
  • Take care getting in and out of the bath or shower as the surface becomes slippery.
  • Pat the skin dry and apply your leave-on emollient afterwards.

Evidence & guidelines

The MHRA has issued repeated safety alerts on the fire risk of paraffin-based and other emollients, and the BATHE trial questioned added benefit of bath emollients in childhood eczema.

Reference: NICE CKS Eczema; BAD; MHRA Drug Safety Update; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.